Wisplinghoff laboratories, Cologne, Germany.
Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
Euro Surveill. 2023 May;28(19). doi: 10.2807/1560-7917.ES.2023.28.19.2200568.
IntroductionEmpirical therapy for the treatment of urinary tract infections should be tailored to the current distribution and susceptibility of potential pathogens to ensure optimal treatment.AimWe aimed to provide an up-to-date overview of the epidemiology and susceptibility of Enterobacterales isolated from urine in Germany.MethodsWe retrospectively analysed antimicrobial susceptibility data from 201,152 urine specimens collected between January 2016 and June 2021 from in- and outpatients. Multiple logistic regression analysis was used to evaluate the association between year of investigation and antibiotic resistance, adjusted for age, sex and species subgroup. Subgroup analyses were performed for midstream urine samples obtained from (i) female outpatients aged 15 to 50 years, (ii) female outpatients older than 50 years and (iii) male outpatients.ResultsResistance rates of less than 20% were observed for nitroxoline (3.9%), fosfomycin (4.6%), nitrofurantoin (11.7%), cefuroxime (13.5%) and ciprofloxacin (14.2%). Resistance to trimethoprim/sulfamethoxazole (SXT) (20.1%), amoxicillin-clavulanic acid (20.5%), trimethoprim (24.2%), pivmecillinam (29.9%) and ampicillin (53.7%) was considerably higher. In the subgroup of outpatient women aged 15-50 years, resistance rates were generally lower. Resistance rates of all antibiotics decreased from 2016 to 2021. Multiple logistic regression revealed the lowest adjusted odds ratio (ORadj) of 0.838 (95% confidence interval (CI): 0.819-0.858; p < 0.001) for pivmecillinam and the highest ORadj of 0.989 (95% CI: 0.972-1.007; p = 0.226) for nitrofurantoin.ConclusionsResistance has generally decreased over the past years, independent of sex, age and causative pathogen. Our data provide an important basis for empirical antibiotic recommendations in various settings and patient collectives.
为确保最佳治疗效果,针对尿路感染的经验性治疗应根据当前潜在病原体的分布和药敏情况进行调整。
本研究旨在提供德国分离的尿肠杆菌科细菌的流行病学和药敏最新概述。
我们回顾性分析了 201152 份 2016 年 1 月至 2021 年 6 月间来自住院和门诊患者的尿液标本的药敏数据。采用多变量逻辑回归分析评估了调查年份与抗生素耐药性之间的相关性,同时调整了年龄、性别和种属亚组的因素。亚组分析包括:(i)15-50 岁女性门诊患者的中段尿样,(ii)50 岁以上女性门诊患者的中段尿样,以及(iii)男性门诊患者的中段尿样。
低于 20%的耐药率见于硝呋太尔(3.9%)、磷霉素(4.6%)、呋喃妥因(11.7%)、头孢呋辛(13.5%)和环丙沙星(14.2%)。而对于复方磺胺甲噁唑(SXT)(20.1%)、阿莫西林克拉维酸(20.5%)、甲氧苄啶(24.2%)、匹美西林(29.9%)和氨苄西林(53.7%)的耐药率则明显较高。在 15-50 岁女性门诊患者亚组中,一般耐药率较低。所有抗生素的耐药率从 2016 年至 2021 年逐渐降低。多变量逻辑回归显示,匹美西林的调整后比值比(ORadj)最低,为 0.838(95%置信区间:0.819-0.858;p<0.001),而呋喃妥因的 ORadj 最高,为 0.989(95%置信区间:0.972-1.007;p=0.226)。
近年来,无论性别、年龄和病原体种类如何,耐药性总体呈下降趋势。本研究数据为不同环境和患者群体中经验性抗生素推荐提供了重要依据。